Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.

Chan DT, Irish AB, Dogra GK, Watts GF.

Atherosclerosis. 2008 Feb;196(2):823-34. Epub 2007 Mar 6. Review.

PMID:
17343861
2.

Dyslipidaemia in chronic kidney disease.

Krane V, Wanner C.

Minerva Urol Nefrol. 2007 Sep;59(3):299-316. Review.

PMID:
17912226
3.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

4.

Cardiovascular disease in patients with renal disease: the role of statins.

Fellström B, Holdaas H, Jardine AG, Svensson MK, Gottlow M, Schmieder RE, Zannad F; AURORA Study Group.

Curr Med Res Opin. 2009 Jan;25(1):271-85. doi: 10.1185/03007990802622064 . Review.

PMID:
19210158
5.

Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Vaziri ND, Norris KC.

Blood Purif. 2013;35(1-3):31-6. doi: 10.1159/000345176. Epub 2013 Jan 22. Review.

6.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
7.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
8.

Statins and lipid-lowering strategies in cardiorenal patients.

Bianchi S, Grimaldi D, Bigazzi R.

Contrib Nephrol. 2011;171:143-50. doi: 10.1159/000327139. Epub 2011 May 23. Review.

PMID:
21625103
9.

[Statins and kidney disease].

Bigazzi R, Grimaldi D, Bianchi S.

G Ital Nefrol. 2012 Mar-Apr;29(2):160-73. Review. Italian.

PMID:
22538946
10.
11.

Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.

Kanbay M, Turgut F, Covic A, Goldsmith D.

J Nephrol. 2009 Sep-Oct;22(5):598-609. Review.

PMID:
19809992
12.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
14.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
15.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
16.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
17.

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Marrs JC, Saseen JJ.

Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823. Review.

PMID:
20653359
18.

Statins and diabetes.

Carmena R, Betteridge DJ.

Semin Vasc Med. 2004 Nov;4(4):321-32. Review.

PMID:
15861314
19.

Evidence-based statin prescription for cardiovascular protection in renal impairment.

Fabbian F, De Giorgi A, Pala M, Tiseo R, Manfredini R, Portaluppi F.

Clin Exp Nephrol. 2011 Aug;15(4):456-63. doi: 10.1007/s10157-011-0454-9. Epub 2011 May 10. Review.

PMID:
21556807
20.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

Items per page

Supplemental Content

Write to the Help Desk